Abstract
Increased cardiac release of norepinephrine (NE) and depleted cardiac stores of NE are two salient features of the human failing heart. Researchers from my laboratory have shown that these changes are accompanied by a functional defect of NE uptake in the cardiac sympathetic nerve terminals. Our studies have shown that the decrease of NE uptake is caused by reduction of NE transporter density in the sympathetic nerve endings, and this change is responsible, at least in part, for the increased myocardial interstitial NE, decreased myocardial adrenoceptor density, and increased myocyte apoptosis in experimental cardiomyopathies. We have also provided evidence in both intact animals and cultured PC12 cells that the decrease of NE transporter is induced by the actions of oxidative metabolites of exogenous NE, involving endoplasmic reticulum stress and impaired N-glycosylation of the NE transporter. This change in the cardiac sympathetic NE uptake function, as demonstrated by [123I] metaiodobenzylguanidine in human studies, may not only serve as an important prognostic variable in patients with congestive heart failure, but also be used as a surrogate for the efficacies of various therapeutic interventions for heart failure. Finally, increasing evidence suggests and further studies are needed to show that the cardiac sympathetic nerve terminal function may be a direct target for pharmacologic treatment of congestive heart failure.
Similar content being viewed by others
Article PDF
References
Braunwald E . Alterations in the activity of the adrenergic nervous system in heart failure. UCLA Forum Med Sci 1970; 10: 289–94.
Chidsey CA, Braunwald E . Sympathetic activity and neurotransmitter depletion in congestive heart failure. Pharmacol Rev 1966; 18: 685–700.
Pool PE, Covell JW, Levitt M, Gibb J, Braunwald E . Reduction of cardiac tyrosine hydroxylase activity in experimental congestive heart failure. Its role in the depletion of cardiac norepinephrine stores. Circ Res 1967; 20: 349–53.
Dequattro V, Nagatsu T, Mendez A, Verska J . Determinants of cardiac noradrenaline depletion in human congestive failure. Cardiovasc Res 1973; 7: 344–50.
Eisenhofer G, Friberg P, Rundqvist B, Quyyumi AA, Lambert G, Kaye DM, et al. Cardiac sympathetic nerve function in congestive heart failure. Circulation 1996; 93: 1667–76.
Spann JF, Sonnenblick EH, Cooper T, Chidsey CA, Willman VL, Braunwald E . Cardiac norepinephrine stores and the contractile state of heart muscle. Circ Res 1966; 19: 317–25.
Spann JF Jr, Chidsey CA, Pool PE, Braunwald E . Mechanism of norepinephrine depletion in experimental heart failure produced by aortic constriction in the guinea pig. Circ Res 1965; 17: 312–21.
Böhm M, La Rosée K, Schwinger RHG, Erdmann E . Evidence of reduction of norepinephrine uptake sites in the failing human heart. J Am Coll Cardiol 1995; 25: 146–53.
Blakely RD, De Felice LJ, Hartzell HC . Molecular physiology of norepinephrine and serotonin transporters. Trends Pharmacol Sci 1991; 12: 334–7.
Galli A, Blakely RD, DeFelice LJ . Norepinephrine transporters have channel modes of conduction. Proc Natl Acad Sci USA 1996; 93: 8671–6.
Fan THM, Liang CS, Kawashima S, Banerjee SP . Alterations in cardiac β-adrenergic receptor responsiveness and adenylate cyclase system by congestive heart failure in dogs. Eur J Pharmacol 1987; 140: 123–32.
Bristow MR, Minobe W, Rasmusen R, Larrabee P, Skerl L, Klein JW, et al. Adrenergic neuroeffector abnormalities in the failing human heart are produced by local rather than systemic mechanisms. J Clin Invest 1992; 89: 803–15.
Liang CS, Fan THM, Sullebarger JT, Sakamoto S . Decreased adrenergic neuronal uptake activity in experimental right heart failure: a chamber-specific contributor to beta-adrenoceptor down-regulation. J Clin Invest 1989; 84: 1267–75.
Himura Y, Felten SY, Kashiki M, Lewandowski TJ, Delehanty JM, Liang CS . Cardiac noradrenergic nerve terminal abnormalities in dogs with experimental congestive heart failure. Circulation 1993; 88: 1299–309.
Delehanty JM, Himura Y, Elam H, Hood WB Jr, Liang CS . β-Adrenoceptor downregulation in pacing-induced heart failure is associated with increased interstitial NE content. Am J Physiol Heart Circ Physiol 1994; 266: H930–5.
Kawai H, Mohan A, Hagen J, Dong E, Armstrong J, Stevens SY, et al. Alterations in cardiac adrenergic terminal function and β-adrenoceptor density in pacing-induced heart failure. Am J Physiol Heart Circ Physiol 2000; 278: H1708–16.
Leineweber K, Brandt K, Wludyka B, Beilflu B, Pönicke K, Heinroth-Hoffmann I, et al. Ventricular hypertrophy plus neurohumoral activation is necessary to alter the cardiac β-adrenoceptor system in experimental heart failure. Circ Res 2002; 91: 1056–62.
Leineweber K, Seyfarth T, Broddie OE . Chamber-specific alterations of noradrenaline uptake (uptake1) in right ventricles of monocrotaline-treated rats. Br J Pharmacol 2000; 131: 1438–44.
Liang CS, Himura Y, Kashiki M, Stevens SY . Differential pre-and post-synaptic effects of desipramine on cardiac sympathetic nerve terminals in RHF. Am J Physiol Heart Circ Physiol 2002; 283: H1863–72.
Shite J, Dong E, Kawai H, Stevens SY, Liang CS . Selegiline improves cardiac noradrenergic nerve terminal function and β-adrenergic responsiveness in heart failure. Am J Physiol Heart Circ Physiol 2000; 279: H1283–90.
Dong E, Yatani A, Mohan A, Liang CS . Myocardial β-adrenoceptor down-regulation by norepinephrine is linked to reduced norepinephrine uptake activity. Eur J Pharmacol 1999; 384: 17–24.
Liang C, Rounds NK, Dong E, Stevens SY, Shite J, Qin F . Alterations by norepinephrine of cardiac sympathetic nerve terminal function and myocardial β-adrenergic receptor sensitivity in the ferret: normalization by antioxidant vitamins. Circulation 2000; 102: 96–103.
Liang CS, Yatani A, Himura Y, Kashiki M, Stevens SY . Desipramine attenuates loss of cardiac sympathetic neurotransmitters produced by congestive heart failure and NE infusion. Am J Physiol Heart Circ Physiol 2003; 284: H1729–36.
Shite J, Qin F, Mao W, Kawai H, Stevens SY, Liang CS . Antioxidant vitamins attenuate oxidative stress and cardiac dysfunction in tachycardia-induced cardiomyopathy. J Am Coll Cardiol 2001; 38: 1734–40.
Mao W, Iwai C, Qin F, Liang CS . Norepinephrine induces endoplasmic reticulum stress and downregulation of norepinephrine transporter density in PC12 cells via oxidative stress. Am J Physiol Heart Circ Physiol 2005; 288: H2381–9.
Mao W, Qin F, Iwai C, Vulapalli R, Keng PC, Liang CS . Extracellular norepinephrine reduces neuronal uptake of norepinephrine by oxidative stress in PC12 cells. Am J Physiol Heart Circ Physiol 2004; 287: H29–39.
Backs J, Haunstetter A, Gerber SH, Metz J, Borst MM, Strausser RH, et al. The neuronal norepinephrine transporter in experimental heart failure: evidence for a posttranscription downregulation. J Mol Cell Cardiol 2001; 33: 461–72.
Böhm M, Castellano M, Flesch M, Maach C, Moll M, Paul M, et al. Chamber-specific alterations of norepinephrine uptake site in cardiac hypertrophy. Hypertension 1998; 32: 831–7.
Backs J, Bresch E, Lutz M, Kristen AV, Haass M . Endothelin-1 inhibits the neuronal norepinephrine transporter in hearts of male rats. Cardiovasc Res 2005; 67: 283–90.
Moe GW, Albernaz A, Naik GO, Kirchengast M, Stewart DJ . Beneficial effects of long-term selective endothlin type A receptor blockade in canine experimental heart failure. Cardiovasc Res 1998; 39: 571–9.
Yamauchi-Kohno R, Miyauchi T, Hoshino T, Kobayashi T, Aihara H, Sakai S, et al. Role of endothelin in deterioration of heart failure due to cardiomyopathy in hamsters. Increase in endothelin-1 production in the heart and beneficial effect of endothelin-A receptor antagonist on survival and cardiac function. Circulation 1999; 99: 2171–6.
Anand I, McMurray J, Cohn JN, Konstam MA, Notter T, Quitzau K, et al. For EARTH investigators. Long-term effects of darusentan on left-ventricular remodeling and clinical outcomes in the Endothelin A Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. Lancet 2004; 364: 347–54.
Kalra PR, Moon JC, Coates AJ . Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? Int J Cardiol 2002; 85: 195–7.
Patel AD, Iskandrian AE . MIBG imaging. J Nucl Cardiol 2002; 9: 75–94.
Henderson EB, Kahn JK, Corbett JR, Jansen DE, Pippin JJ, Kulkarni P, et al. Abnormal I-123 metaiodobenzylguanidine myocardial washout and distribution may reflect myocardial adrenergic derangement in patients with congestive cardiomyopathy. Circulation 1988; 78: 1192–9.
Ohshima S, Isobe S, Izawa H, Nanasato M, Ando A, Yamada A, et al. Cardiac sympathetic dysfunction correlates with abnormal myocardial contractile reserve in dilated cardiomyopathic patients. J Am Coll Cardiol 2005; 46: 2061–8.
Ungerer M, Hartmann F, Karoglan M, Chlistalla A, Ziegler S, Richardt G, et al. Regional in vivo and in vitro characterization of autonomic innervation in cardiomyopathic human heart. Circulation 1998; 97: 174–80.
Merlet P, Benvenuti C, Moyse D, Pouillart F, Dubois-Randé JL, Duval AM, et al. Prognostic value of MIBG imaging in idiopathic dilated cardiomyopathy. J Nucl Med 1999; 40: 917–23.
Yamada T, Shimonagata T, Fukunami M, Kumagai K, Ogita H, Hirata A, et al. Comparison of the prognostic value of cardiac iodine-123 metaiodobenzylguanidine imaging and heart rate variability in patients with chronic heart failure: a prospective study. J Am Coll Cardiol 2003; 41: 231–8.
Lotze U, Kaepplinger S, Kober A, Richartz BM, Gottschild D, Figulla HR . Recovery of the cardiac adrenergic nervous system after long-term β-blocker therapy in idiopathic dilated cardiomyopathy: assessment by increase in myocardial 123I-metaiodobenzylguanidine uptake. J Nucl Med 2001; 42: 49–54.
de Milliano PAR, de Groot AC, Tijssen JGP, van Eck-Smit BLF, Van Zwieten PA, Lie KI . Beneficial effects of metoprolol on myocardial sympathetic function: evidence from a randomized, placebo-controlled study in patients with congestive heart failure. Am Heart J 2002; 144: E3.
Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, et al. Spironolactone improves cardiac sympathetic nerve activity and symptoms in patients with congestive heart failure. J Nucl Med 2002; 43: 1279–85.
Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, et al. Effect of spironolactone on cardiac sympathetic nerve activity and left ventricular remodeling in patients with dilated cardiomyopathy. J Am Coll Cardiol 2003; 41: 474–81.
Somsen GA, van Vlies B, de Miliano PA, Borm JJ, van Royen EA, Endert E, et al. Increased myocardial [123I]-metaiodobenzylguanidine uptake after enalapril treatment in patients with chronic heart failure. Heart 1996; 76: 218–22.
Erol-Yilmaz A, Verberne HJ, Schrama TA, Hrudova J, De Winter RJ, Van Eck-Smit BLF, et al. Cardiac resynchronization induces favorable neurohumoral changes. Pacing Clin Electrophysiol 2005; 28: 304–10.
The Beta-Blocker Evaluation of Survival Trial investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001; 344: 1659–67.
Eichhorn EJ, McGhie AL, Bedotto JB, Corbett JR, Malloy CR, Hatfield BA, et al. Effects of bucindolol on neurohormonal activation in congestive heart failure. Am J Cardiol 1991; 67: 67–73.
Motherwell DW, Petrie MC, Martin W, Cobbe SM . 123I-metaiodobenzylguanidine in chronic heart failure: is there a clinical use? Nucl Med Commun 2006; 27: 927–31.
Bristow MR . β-Adrenergic receptor blockade in chronic heart failure. Circulation 2000; 101: 558–69.
Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. for the US Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996; 334: 1349–55.
The Cardiac Insufficiency Bisoprolol Study (CIBIS-II): a randomized trial. Lancet 1999; 353: 9–13.
MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF). Lancet 1999; 353: 2001–7.
Ziegler D, Haxhiu MA, Kaan EC, Papp JG, Ernsberger P . Pharmacology of moxonidine: an I1-imidazoline receptor agonist. J Cardiovasc Pharmacol 1996; 27 ( Suppl 3): S26–37.
Dickstein K, Manhenke C, Aarsland T, Køff U, McNay J, Wiltse C . Acute hemodynamic and neurohumoral effects of moxonidine in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1999; 83: 1638–44.
Azevdeo ER, Newton GE, Parker JD . Cardiac and systemic sympathetic activity in response to clonidine in human heart failure. J Am Coll Cardiol 1999; 33: 186–91.
Cohn JN, Pfeffer MA, Rouleau J, Sharpe N, Swedberg K, Straub M, et al. for the MOXCON investigators. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail 2003; 5: 659–67.
Kreusser MM, Haass M, Buss S, Hardt SE, Gerber SH, Kinscherf R, et al. Injection of nerve growth factor into stellate ganglia improves norepinephrine reuptake into failing hearts. Hypertension 2006; 47: 209–15.
Münch G, Rosport K, Bültmann A, Baumgartner C, Li Z, Laacke L, et al. Cardiac overexpression of the norepinephrine transporter uptake-1 results in marked improvement of heart failure. Circ Res 2005; 97: 928–36.
Author information
Authors and Affiliations
Corresponding author
Additional information
Project supported by a grant from USPHS National Heart, Lung, and Blood Institute (No HL-68151).
Rights and permissions
About this article
Cite this article
Liang, Cs. Cardiac sympathetic nerve terminal function in congestive heart failure. Acta Pharmacol Sin 28, 921–927 (2007). https://doi.org/10.1111/j.1745-7254.2007.00585.x
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1111/j.1745-7254.2007.00585.x
Keywords
This article is cited by
-
NADPH oxidase 2 mediates cardiac sympathetic denervation and myocyte autophagy, resulting in cardiac atrophy and dysfunction in doxorubicin-induced cardiomyopathy
Scientific Reports (2024)
-
Autonomic control of ventricular function in health and disease: current state of the art
Clinical Autonomic Research (2023)
-
Cardiac Sympathetic Innervation Imaging with PET Radiotracers
Current Cardiology Reports (2021)
-
Cardiac innervation imaging as a risk stratification tool for potential device therapy candidates
Journal of Nuclear Cardiology (2020)
-
Ventricular Distribution Pattern of the Novel Sympathetic Nerve PET Radiotracer 18F-LMI1195 in Rabbit Hearts
Scientific Reports (2019)